Q2 2022 SanBio Co Ltd Earnings Call Transcript
Good afternoon. This is Keita Mori from SanBio. Thank you for all the investors and other people to attending this meeting today. It's a pleasure for us to present to this many audiences today.
We met the 20 years anniversary this year, earlier this year. And we continue to strive towards developing pioneering regenerative medicine and developing the first brain regenerative medicine, which has been wanted for more than, I guess, 100 years or so.
So we have 3 contents today starting from the financial results. First, I'd like to go over the income statement. As you can see, the R&D, research and development expenses increased due to higher manufacturing-related expenses in preparation for approval filing of SB623 for TBI. As you can see, our R&D expense was about $22 million in the last 6 months, and that there is some increase, again, from the additional expenses in the manufacturing.
Next, I'd like to go to the balance sheet. As we are continuing to be still in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
